For those interested, see below the relevant charts relating to (1) tumor burden; and (2) survival curves for CF33 in a nude mouse model. This is only pre-clinical evidence and should not be treated as evidence for efficacy in humans for obvious reasons. Retrieved from Woo et al (2020).
Figure 4 - Tumour Burden
Figure 5 - Survival Curves
Hope this helps. As always, DYOR!
Ann: Imugene to Present Oncolytic Virus Data at AACR21 Meeting, page-11
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.1¢ | 4.8¢ | $1.062M | 21.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 5138497 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 6291273 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |